Advertisement

Miscellaneous Metastases

  • Andrew Dhawan
  • David PeereboomEmail author
Chapter

Abstract

While the majority of cancers metastatic to the central nervous system arise from lung, breast, or melanoma primary tumors, approximately 20–30% arise from other primary tumor sites. In particular, renal cell carcinoma, thyroid tumors, GI cancers (colorectal), germ cell tumors, gynecologic neoplasms (uterine and placental), hematopoietic cancers (lymphoma and leukemia), as well as genitourinary cancers (prostate and bladder) can metastasize to the brain. While these individual histologies rarely metastasize to the CNS, together they represent a sizeable and increasing number of patients as they live longer with improving therapy for their systemic disease and with earlier detection of CNS metastasis. In general, each of these metastases is treated with some combination of whole-brain radiation (WBRT), stereotactic radiosurgery (SRS), systemic chemotherapy, intrathecal chemotherapy, or novel agents, such as immunotherapeutics. In this chapter, we will review the evidence for the management of each of these less common metastases to the brain, with a focus also on the emerging treatments and current research in this area.

Keywords

CNS metastasis Renal cell carcinoma Thyroid cancer Gastrointestinal cancer Germ cell tumors Gynecologic cancers Leukemia Lymphoma Prostate cancer Bladder cancer 

Notes

Acknowledgment

Disclosures: DP: None.

References

  1. 1.
    Saitoh H. Distant metastasis of renal adenocarcinoma. Cancer. 1981;48(6):1487–91.PubMedCrossRefGoogle Scholar
  2. 2.
    Harada Y, Nonomura N, Kondo M, Nishimura K, Takahara S, Miki T, et al. Clinical study of brain metastasis of renal cell carcinoma. Eur Urol. 1999;36(3):230–5.PubMedCrossRefGoogle Scholar
  3. 3.
    Schouten LJ, Rutten J, Huveneers HA, Twijnstra A. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer. 2002;94(10):2698–705.Google Scholar
  4. 4.
    Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol. 2004;22(14):2865–72.CrossRefGoogle Scholar
  5. 5.
    Haque W, Verma V, Butler EB, Teh BS. Utilization of stereotactic radiosurgery for renal cell carcinoma brain metastases. Clin Genitourin Cancer. 2018;16(4):e935–e43.PubMedCrossRefGoogle Scholar
  6. 6.
    Sheehan JP, Sun M-H, Kondziolka D, Flickinger J, Lunsford LD. Radiosurgery in patients with renal cell carcinoma metastasis to the brain: long-term outcomes and prognostic factors influencing survival and local tumor control. J Neurosurg. 2003;98(2):342–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Barata PC, Mendiratta P, Kotecha R, Gopalakrishnan D, Juloori A, Chao ST, et al. Effect of switching systemic treatment after stereotactic radiosurgery for oligoprogressive, metastatic renal cell carcinoma. Clin Genitourin Cancer. 2018;16:413–419.e1.PubMedCrossRefGoogle Scholar
  8. 8.
    Mori Y, Kondziolka D, Flickinger JC, Logan T, Lunsford LD. Stereotactic radiosurgery for brain metastasis from renal cell carcinoma. Cancer. 1998;83(2):344–53.PubMedCrossRefGoogle Scholar
  9. 9.
    Choueiri TK, Motzer RJ. Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med. 2017;376(4):354–66.PubMedCrossRefGoogle Scholar
  10. 10.
    Chen L, Douglass J, Kleinberg L, Ye X, Marciscano AE, Forde PM, et al. Concurrent immune checkpoint inhibitors and stereotactic radiosurgery for brain metastases in non-small cell lung cancer, melanoma, and renal cell carcinoma. Int J Radiat Oncol Biol Phys. 2018;100(4):916–25.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Sperduto PW, Deegan BJ, Li J, Jethwa KR, Brown PD, Lockney N, et al. Effect of targeted therapies on prognostic factors, patterns of care, and survival in patients with renal cell carcinoma and brain metastases. Int J Radiat Oncol Biol Phys. 2018;101(4):845–53.PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Chiu AC, Delpassand ES, Sherman SI. Prognosis and treatment of brain metastases in thyroid carcinoma. J Clin Endocrinol Metabol. 1997;82(11):3637–42.CrossRefGoogle Scholar
  13. 13.
    Choi J, Kim JW, Keum YS, Lee IJ. The largest known survival analysis of patients with brain metastasis from thyroid cancer based on prognostic groups. PLoS One. 2016;11(4):e0154739.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Lemke J, Scheele J, Kapapa T, von Karstedt S, Wirtz CR, Henne-Bruns D, et al. Brain metastases in gastrointestinal cancers: is there a role for surgery? Int J Mol Sci. 2014;15(9):16,816–30.CrossRefGoogle Scholar
  15. 15.
    Song Z, Lin B, Shao L, Zhang Y. Brain metastases from esophageal cancer: clinical review of 26 cases. World Neurosurg. 2014;81(1):131–5.PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Wadhwa R, Taketa T, Correa AM, Sudo K, Campagna MC, Blum MA, et al. Incidence of brain metastases after trimodality therapy in patients with esophageal or gastroesophageal cancer: implications for screening and surveillance. Oncology. 2013;85(4):204–7.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Kim M. Intracranial involvement by metastatic advanced gastric carcinoma. J Neurooncol. 1999;43(1):59–62.PubMedCrossRefGoogle Scholar
  18. 18.
    Park YS, Chang JH, Chang JW, Park YG. The efficacy of gamma knife radiosurgery for advanced gastric cancer with brain metastases. J Neurooncol. 2011;103(3):513–21.PubMedCrossRefGoogle Scholar
  19. 19.
    Han JH, Kim DG, Chung HT, Kim CY, Park CK, Chung YS, et al. Radiosurgery for brain metastasis from advanced gastric cancer. Acta Neurochir. 2010;152(4):605–10.PubMedCrossRefGoogle Scholar
  20. 20.
    Kasakura Y, Fujii M, Mochizuki F, Suzuki T, Takahashi T. Clinicopathological study of brain metastasis in gastric cancer patients. Surg Today. 2000;30(6):485–90.PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    Kraszkiewicz M, Wydmanski J. Brain metastases from stomach cancer–the role of different treatment modalities and efficacy of palliative radiotherapy. Rep Pract Oncol Radiother. 2015;20(1):32–7.PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    York JE, Stringer J, Ajani JA, Wildrick DM, Gokaslan ZL. Gastric cancer and metastasis to the brain. Ann Surg Oncol. 1999;6(8):771–6.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Park KS, Kim M, Park SH, Lee KW. Nervous system involvement by pancreatic cancer. J Neurooncol. 2003;63(3):313–6.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Go PH, Klaassen Z, Meadows MC, Chamberlain RS. Gastrointestinal cancer and brain metastasis. Cancer. 2011;117(16):3630–40.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Aprile G, Zanon E, Tuniz F, Iaiza E, De Pauli F, Pella N, et al. Neurosurgical management and postoperative whole-brain radiotherapy for colorectal cancer patients with symptomatic brain metastases. J Cancer Res Clin Oncol. 2009;135(3):451–7.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Jung M, Ahn JB, Chang JH, Suh CO, Hong S, Roh JK, et al. Brain metastases from colorectal carcinoma: prognostic factors and outcome. J Neurooncol. 2011;101(1):49–55.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Damiens K, Ayoub JP, Lemieux B, Aubin F, Saliba W, Campeau MP, et al. Clinical features and course of brain metastases in colorectal cancer: an experience from a single institution. Curr Oncol. 2012;19(5):254–8.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Baek JY, Kang MH, Hong YS, Kim TW, Kim DY, Oh JH, et al. Characteristics and prognosis of patients with colorectal cancer-associated brain metastases in the era of modern systemic chemotherapy. J Neurooncol. 2011;104(3):745–53.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Kruser TJ, Chao ST, Elson P, Barnett GH, Vogelbaum MA, Angelov L, et al. Multidisciplinary management of colorectal brain metastases: a retrospective study. Cancer. 2008;113(1):158–65.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Forquer JA, Harkenrider M, Fakiris AJ, Timmerman RD, Cavaliere R, Henderson MA, et al. Brain metastasis from non-seminomatous germ cell tumor of the testis. Expert Rev Anticancer Ther. 2007;7(11):1567–80.PubMedCrossRefGoogle Scholar
  31. 31.
    Culine S, Kerbrat P, Kramar A, Theodore C, Chevreau C, Geoffrois L, et al. Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP). Ann Oncol. 2007;18(5):917–24.PubMedCrossRefGoogle Scholar
  32. 32.
    de Wit R, Stoter G, Kaye SB, Sleijfer DT, Jones WG, ten Bokkel Huinink WW, et al. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol. 1997;15(5):1837–43.PubMedCrossRefGoogle Scholar
  33. 33.
    Bosl GJ, Geller NL, Bajorin D, Leitner SP, Yagoda A, Golbey RB, et al. A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors. J Clin Oncol. 1988;6(8):1231–8.PubMedCrossRefGoogle Scholar
  34. 34.
    Logothetis CJ, Samuels ML, Trindade A. The management of brain metastases in germ cell tumors. Cancer. 1982;49(1):12–8.PubMedCrossRefGoogle Scholar
  35. 35.
    Gerl A, Clemm C, Kohl P, Schalhorn A, Wilmanns W. Central nervous system as sanctuary site of relapse in patients treated with chemotherapy for metastatic testicular cancer. Clin Exp Metastasis. 1994;12(3):226–30.PubMedCrossRefGoogle Scholar
  36. 36.
    Feldman DR, Lorch A, Kramar A, Albany C, Einhorn LH, Giannatempo P, et al. Brain metastases in patients with germ cell tumors: prognostic factors and treatment options—an analysis from the global germ cell cancer group. J Clin Oncol. 2016;34(4):345–51.PubMedCrossRefGoogle Scholar
  37. 37.
    Growdon WB, Lopez-Varela E, Littell R, Oliva E, Seiden M, Krasner C, et al. Extent of extracranial disease is a powerful predictor of survival in patients with brain metastases from gynecological cancer. Int J Gynecol Cancer. 2008;18(2):262–8.PubMedCrossRefGoogle Scholar
  38. 38.
    Takeshita S, Todo Y, Furuta Y, Okamoto K, Minobe S, Yamashiro K, et al. Prognostic factors for patients with brain metastasis from gynecological cancer: a significance of treatment-free interval of more than 6 months. Jpn J Clin Oncol. 2017;47(7):604–10.PubMedCrossRefGoogle Scholar
  39. 39.
    Kobayashi T, Kida Y, Yoshida J, Shibuya N, Kageyama N. Brain metastasis of choriocarcinoma. Surg Neurol. 1982;17(6):395–403.PubMedCrossRefGoogle Scholar
  40. 40.
    Athanassiou A, Begent RHJ, Newlands ES, Parker D, Rustin GJS, Bagshawe KD. Central nervous system metastases of choriocarcinoma. 23 Years’ experience at Charing Cross Hospital. Cancer. 1983;52(9):1728–35.PubMedCrossRefGoogle Scholar
  41. 41.
    Altintas A, Vardar MA. Central nervous system involvement in gestational trophoblastic neoplasia. Eur J Gynaecol Oncol. 2001;22(2):154–6.PubMedGoogle Scholar
  42. 42.
    Savage P, Kelpanides I, Tuthill M, Short D, Seckl MJ. Brain metastases in gestational trophoblast neoplasia: an update on incidence, management and outcome. Gynecol Oncol. 2015;137(1):73–6.PubMedCrossRefGoogle Scholar
  43. 43.
    Lybol C, Thomas CMG, Blanken EA, Sweep FCGJ, Verheijen RH, Westermann AM, et al. Comparing cisplatin-based combination chemotherapy with EMA/CO chemotherapy for the treatment of high risk gestational trophoblastic neoplasia. Eur J Cancer. 2013;49(4):860–7.PubMedCrossRefGoogle Scholar
  44. 44.
    Nayak L, Pentsova E, Batchelor TT. Primary CNS lymphoma and neurologic complications of hematologic malignancies. Continuum. 2015;21(2, Neuro-oncology):355–72.PubMedGoogle Scholar
  45. 45.
    Olson ME, Chernik NL, Posner JB. Infiltration of the leptomeninges by systemic cancer: a clinical and pathologic study. Arch Neurol. 1974;30(2):122–37.PubMedCrossRefGoogle Scholar
  46. 46.
    DeAngelis LM. Current diagnosis and treatment of leptomeningeal metastasis. J Neurooncol. 1998;38(2-3):245–52.PubMedCrossRefGoogle Scholar
  47. 47.
    Recht L, Straus DJ, Cirrincione C, Thaler HT, Posner JB. Central nervous system metastases from non-Hodgkin’s lymphoma: treatment and prophylaxis. Am J Med. 1988;84(3 Pt 1):425–35.PubMedCrossRefGoogle Scholar
  48. 48.
    Leal T, Chang JE, Mehta M, Robins HI. Leptomeningeal metastasis: challenges in diagnosis and treatment. Curr Cancer Ther Rev. 2011;7(4):319–27.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Glantz MJ, LaFollette S, Jaeckle KA, Shapiro W, Swinnen L, Rozental JR, et al. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol. 1999;17(10):3110–6.PubMedCrossRefGoogle Scholar
  50. 50.
    Fischer L, Korfel A, Kiewe P, Neumann M, Jahnke K, Thiel E. Systemic high-dose methotrexate plus ifosfamide is highly effective for central nervous system (CNS) involvement of lymphoma. Ann Hematol. 2009;88(2):133–9.PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Schorb E, Kasenda B, Atta J, Kaun S, Morgner A, Hess G, et al. Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation. Haematologica. 2013;98(5):765–70.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Korfel A, Elter T, Thiel E, Hänel M, Möhle R, Schroers R, et al. Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas. Haematologica. 2013;98(3):364–70.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Tremont-Lukats IW, Bobustuc G, Lagos GK, Lolas K, Kyritsis AP, Puduvalli VK. Brain metastasis from prostate carcinoma: the M. D. Anderson Cancer Center experience. Cancer. 2003;98(2):363–8.PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Hatzoglou V, Patel GV, Morris MJ, Curtis K, Zhang Z, Shi W, et al. Brain metastases from prostate cancer: an 11-year analysis in the MRI era with emphasis on imaging characteristics, incidence, and prognosis. J Neuroimaging. 2014;24(2):161–6.PubMedCrossRefPubMedCentralGoogle Scholar
  55. 55.
    de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995–2005.PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Benoist GE, Hendriks RJ, Mulders PFA, Gerritsen WR, Somford DM, Schalken JA, et al. Pharmacokinetic aspects of the two novel oral drugs used for metastatic castration-resistant prostate cancer: abiraterone acetate and enzalutamide. Clin Pharmacokinet. 2016;55(11):1369–80.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Rosenstein M, Wallner K, Scher H, Sternberg CN. Treatment of brain metastases from bladder cancer. J Urol. 1993;149(3):480–3.PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    Mahmoud-Ahmed AS, Suh JH, Kupelian PA, Klein EA, Peereboom DM, Dreicer R, et al. Brain metastases from bladder carcinoma: presentation, treatment and survival. J Urol. 2002;167(6):2419–22.PubMedCrossRefPubMedCentralGoogle Scholar
  59. 59.
    Wen PY, Schiff D, Cloughesy TF, Reardon DA, Batchelor TT, Chabner BA, et al. It is time to include patients with brain tumors in phase I trials in oncology. J Clin Oncol. 2011;29(24):3211–13.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Cleveland Clinic FoundationClevelandUSA

Personalised recommendations